Streamlining Anthem (Elevance Health) Prior Authorization for Hematology

Key Hematology Services Requiring Anthem Prior Authorization

Hematology services frequently flagged for prior authorization by Anthem (Elevance Health) include a range of high-cost therapeutics and specialized procedures. These often involve complex documentation requirements and specific clinical criteria, requiring precise attention to detail during submission.

High-Volume Prior Authorization Categories

• Hemophilia factor concentrates (e.g., factor VIII, factor IX) for prophylaxis and on-demand treatment.
• Specialty drugs for sickle cell disease (e.g., voxelotor, crizanlizumab, gene therapies).
• Hematologic oncology treatments, including CAR-T cell therapies (e.g., Yescarta, Kymriah) and biologics for lymphomas, leukemias, and multiple myeloma, often guided by NCCN compendium.
• Specialty imaging for diagnostic workups and monitoring of conditions like multiple myeloma (MM) and MGUS.
• Bone marrow and stem cell transplant procedures (autologous and allogeneic).

Anthem's Prior Authorization Submission Channels for Hematology

Anthem-licensed plans utilize a multi-channel approach for prior authorization submissions. Medical benefit PAs for hematology services, including many specialty injectables and infusions, are primarily submitted through Availity Essentials, which also supports X12 278 transactions via clearinghouses. Pharmacy benefit medications are managed by CarelonRx, accepting ePA through CoverMyMeds and Surescripts. For advanced imaging relevant to hematology, submissions route through Carelon Medical Benefits Management's dedicated provider portal, distinct from the standard medical PA channel.

Clinical Criteria and Policy Access for Hematology PAs

Anthem operating companies publish medical policies and clinical utilization management guidelines through provider sites accessible via Availity. For hematologic oncology, these policies frequently reference NCCN compendium criteria. For procedures managed by Carelon Medical Benefits Management, such as specialty imaging, the clinical guidelines are published on the Carelon MBM provider site. Adherence to specific ASH guidelines for conditions like hemophilia and sickle cell disease, and NCCN for hematologic oncology, is critical for successful authorization.

Common Denial Patterns and Appeals for Hematology with Anthem

Denials for hematology PAs with Anthem often stem from medical necessity gaps, particularly concerning NCCN compendium alignment for novel agents, or specific criteria around hemophilia factor prophylaxis versus on-demand use. CAR-T eligibility documentation gaps are also frequent. Site-of-service mismatch denials are common due to Anthem's active site-of-care policies. Appeals for standard medical PAs follow the Anthem operating company's process, while denials for services managed by Carelon Medical Benefits Management have a separate, dedicated appeal pathway.

Klivira's Approach to Anthem Hematology Prior Authorization

Klivira automates the intricate process of Anthem (Elevance Health) prior authorization for hematology, integrating directly with EMRs to streamline submissions. Our platform incorporates ASH and NCCN-aware policy logic, assisting with the complex documentation requirements for high-cost therapies like factor concentrates, sickle cell drugs, and CAR-T. By reducing manual touchpoints and enhancing data accuracy, Klivira helps accelerate approvals and minimize denials, ensuring timely patient access to critical hematologic care.